Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.
The urinary production of pyridinium collagen cross-links, pyridinoline (PYD) and deoxypyridinoline (DPD), has been correlated to increased bone resorption in patients with neoplasms. This study investigated the production of these compounds in patients with metastatic prostate carcinoma who received palliative treatment that did and did not include 89Sr-chloride therapy.


METHODS
Urinary production of PYD and DPD was measured by high-performance liquid chromatography and natural flucrescence detection methods. The urine from several age-matched groups of patients was examined for these compounds including healthy controls (n = 20), patients with early-stage (Stage A-B) prostate carcinoma (n = 8), patients with metastatic prostate carcinoma treated with conventional analgesic and radiotherapeutic palliation (n = 20), patients with metastatic disease who underwent 89Sr-chloride therapy (n = 20) and patients with mild Paget's disease (n = 5). Patients were also monitored for urinary PYD and DPD production for a 6-mo interval after a palliative intervention.


RESULTS
Elevated PYD and DPD (p < 0.05) concentrations were measured in patients with metastatic and nonmetastatic prostate cancer and Paget's disease. The urinary production of these compounds remained unchanged for 6 mo after 89Sr-chloride therapy for symptomatic osseous metastases. However, the patients who did not undergo 89Sr-chloride therapy exhibited a two-fold increase in PYD and a four-fold increase in DPD above controls during the interval.


CONCLUSIONS
PYD and DPD are sensitive and specific bone resorption markers which demonstrate a slowing of bone resorption after palliative 89Sr-chloride therapy in patients with bone metastases.
Papatheofanis
F J
FJ
Department of Radiology, University of California, San Diego 92103-8758, USA.
D000368:Aged; D000596:Amino Acids / Q000652:urine*; D001859:Bone Neoplasms / Q000532:radiotherapy* / Q000556:secondary* / Q000652:urine; D001862:Bone Resorption / Q000652:urine*; D016022:Case-Control Studies; D006801:Humans; D008297:Male; D010001:Osteitis Deformans / Q000652:urine; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000473:pathology*; D013324:Strontium / Q000627:therapeutic use*; D013326:Strontium Radioisotopes / Q000627:therapeutic use*; D013997:Time Factors
D000596:Amino Acids; D013326:Strontium Radioisotopes; C015484:pyridinoline; C036020:deoxypyridinoline; C025700:strontium chloride; D013324:Strontium